New molecules and strategies in the field of anticancer agents

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The conventional chemotherapy is mostly based on the evidence that proliferating cells are more sensitive to anticancer agents than non-dividing cells. This is the main reason why these compounds are not tumour specific and their selectivity is generally in favour of rapidly growing cells (haematopoietic or intestine. i.e.) rather than discriminating against any fundamental biological difference between normal and tumour cells. The critical issue is at present to identify how tumour cells differ from normal cells and how those differences can be exploited therapeutically for designing and synthesising new drugs with a selective mechanism of action and thus with an improved therapeutic index. This topic and the strategies to identify these new targets will be discussed in details in the review. The expanding knowledge on molecular biology of cancer cells has allowed in the last years the identification of different molecular pathways altered in cancer that could be exploited as potential therapeutic targets. For most of the pathways previously disclosed it has been a problem to develop selective molecules with a relevant clinic impact. To target those specific genetics defects, different kind of molecules (antibodies, "antisense oligonucleotides", short peptides and small molecules) have been made and some of them are currently under investigation. This review will be focused mainly on three different classes of compounds: I. Compounds designed to hit or inhibit crucial molecular targets. II. Novel DNA minor groove binders. III. Products of marine origin that exhibit novel mode of action.

Original languageEnglish
Pages (from-to)247-262
Number of pages16
JournalCurrent Medicinal Chemistry - Anti-Cancer Agents
Volume4
Issue number3
DOIs
Publication statusPublished - 2004

Fingerprint

Antineoplastic Agents
Neoplasms
Antisense Oligonucleotides
Intestines
Molecular Biology
Drug Therapy
Peptides
Antibodies
DNA
Therapeutics
Pharmaceutical Preparations

Keywords

  • Cancer chemotherapy target oriented drugs
  • DNA interacting agents
  • Minor groove binders
  • New anticancer drugs

ASJC Scopus subject areas

  • Molecular Medicine
  • Cancer Research
  • Pharmacology

Cite this

@article{60c39057bd7b4e56b0ac4d2095cb3c89,
title = "New molecules and strategies in the field of anticancer agents",
abstract = "The conventional chemotherapy is mostly based on the evidence that proliferating cells are more sensitive to anticancer agents than non-dividing cells. This is the main reason why these compounds are not tumour specific and their selectivity is generally in favour of rapidly growing cells (haematopoietic or intestine. i.e.) rather than discriminating against any fundamental biological difference between normal and tumour cells. The critical issue is at present to identify how tumour cells differ from normal cells and how those differences can be exploited therapeutically for designing and synthesising new drugs with a selective mechanism of action and thus with an improved therapeutic index. This topic and the strategies to identify these new targets will be discussed in details in the review. The expanding knowledge on molecular biology of cancer cells has allowed in the last years the identification of different molecular pathways altered in cancer that could be exploited as potential therapeutic targets. For most of the pathways previously disclosed it has been a problem to develop selective molecules with a relevant clinic impact. To target those specific genetics defects, different kind of molecules (antibodies, {"}antisense oligonucleotides{"}, short peptides and small molecules) have been made and some of them are currently under investigation. This review will be focused mainly on three different classes of compounds: I. Compounds designed to hit or inhibit crucial molecular targets. II. Novel DNA minor groove binders. III. Products of marine origin that exhibit novel mode of action.",
keywords = "Cancer chemotherapy target oriented drugs, DNA interacting agents, Minor groove binders, New anticancer drugs",
author = "S. Marchini and M. D'Incalci and M. Broggini",
year = "2004",
doi = "10.2174/1568011043352966",
language = "English",
volume = "4",
pages = "247--262",
journal = "Current Medicinal Chemistry - Anti-Cancer Agents",
issn = "1568-0118",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - New molecules and strategies in the field of anticancer agents

AU - Marchini, S.

AU - D'Incalci, M.

AU - Broggini, M.

PY - 2004

Y1 - 2004

N2 - The conventional chemotherapy is mostly based on the evidence that proliferating cells are more sensitive to anticancer agents than non-dividing cells. This is the main reason why these compounds are not tumour specific and their selectivity is generally in favour of rapidly growing cells (haematopoietic or intestine. i.e.) rather than discriminating against any fundamental biological difference between normal and tumour cells. The critical issue is at present to identify how tumour cells differ from normal cells and how those differences can be exploited therapeutically for designing and synthesising new drugs with a selective mechanism of action and thus with an improved therapeutic index. This topic and the strategies to identify these new targets will be discussed in details in the review. The expanding knowledge on molecular biology of cancer cells has allowed in the last years the identification of different molecular pathways altered in cancer that could be exploited as potential therapeutic targets. For most of the pathways previously disclosed it has been a problem to develop selective molecules with a relevant clinic impact. To target those specific genetics defects, different kind of molecules (antibodies, "antisense oligonucleotides", short peptides and small molecules) have been made and some of them are currently under investigation. This review will be focused mainly on three different classes of compounds: I. Compounds designed to hit or inhibit crucial molecular targets. II. Novel DNA minor groove binders. III. Products of marine origin that exhibit novel mode of action.

AB - The conventional chemotherapy is mostly based on the evidence that proliferating cells are more sensitive to anticancer agents than non-dividing cells. This is the main reason why these compounds are not tumour specific and their selectivity is generally in favour of rapidly growing cells (haematopoietic or intestine. i.e.) rather than discriminating against any fundamental biological difference between normal and tumour cells. The critical issue is at present to identify how tumour cells differ from normal cells and how those differences can be exploited therapeutically for designing and synthesising new drugs with a selective mechanism of action and thus with an improved therapeutic index. This topic and the strategies to identify these new targets will be discussed in details in the review. The expanding knowledge on molecular biology of cancer cells has allowed in the last years the identification of different molecular pathways altered in cancer that could be exploited as potential therapeutic targets. For most of the pathways previously disclosed it has been a problem to develop selective molecules with a relevant clinic impact. To target those specific genetics defects, different kind of molecules (antibodies, "antisense oligonucleotides", short peptides and small molecules) have been made and some of them are currently under investigation. This review will be focused mainly on three different classes of compounds: I. Compounds designed to hit or inhibit crucial molecular targets. II. Novel DNA minor groove binders. III. Products of marine origin that exhibit novel mode of action.

KW - Cancer chemotherapy target oriented drugs

KW - DNA interacting agents

KW - Minor groove binders

KW - New anticancer drugs

UR - http://www.scopus.com/inward/record.url?scp=2442589578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442589578&partnerID=8YFLogxK

U2 - 10.2174/1568011043352966

DO - 10.2174/1568011043352966

M3 - Article

C2 - 15134503

AN - SCOPUS:2442589578

VL - 4

SP - 247

EP - 262

JO - Current Medicinal Chemistry - Anti-Cancer Agents

JF - Current Medicinal Chemistry - Anti-Cancer Agents

SN - 1568-0118

IS - 3

ER -